ASHG Genetic Diagnosis & Rare Disease Virtual Symposium—Day 2

by Michael D. O’Neill

On Wednesday, December 3, 2025, the American Society of Human Genetics (ASHG) hosted the second day of its two-day virtual symposium on Genetic Diagnosis & Rare Disease. The day began with personal remarks from Helene Cederroth, mother of three young children who all died of an undiagnosed disease and co-founder with her husband Mikk of the Wilhelmina Foundation. Helene is chairperson of the Foundation and Mikk is a board member. The foundation is named after Wilhelm, the first of their children to die and it is dedicated to solve undiagnosed diseases, the diseases that are not known to medical science because no test results match any known disease. The Wilhelm Foundation’s goal is for everyone with an undiagnosed disease to get a diagnosis!

Toward this end, the Wilhelm Foundation has recently organized the so-called ”Undiagnosed Hackathon,” which is a global initiative aimed at diagnosing complex undiagnosed diseases that have eluded traditional medical approaches. Organized by the Wilhelm Foundation, the hackathon brings together multidisciplinary teams—including clinicians, geneticists, bioinformaticians, molecular biologists and AI specialists, and patient advocates—to collaborate intensively over 48 hours and share information on currently undiagnosed diseases.

The 3rd Undiagnosed Hackathon took place from September 21 to 23, 2025, at the Mayo Clinic in Rochester, Minnesota, USA. It was a collaboration between Wilhelm Foundation and Mayo Clinic. This event brought together a global community of clinicians, bioinformaticians, molecular biologists, scientists, developers, AI specialists, and other experts to tackle complex cases of undiagnosed diseases. The fourth Undiagnosed Hackathon will be held in Hyderabad, India, February 3-5, 2026.

Helene was then joined by Eric Klee, PhD, of the Mayo Clinic who amplified on the work of the Undiagnosed Hackathon. Klee conducts research focused on the translational application of omics data in the clinical setting, including novel method and application development. Studies include a focus on rare or undiagnosed Mendelian diseases, development of state-of-the-art analytics applied to novel omics technologies, and identification of novel diagnoses and treatments for patients. Using integrative multi-omics profiling to characterize patients’ molecular states is a primary area of research, involving comprehensive and unbiased transcriptomic profiling and methylation profiling. Klee is engaged in research to push the boundary on how suspected rare or undiagnosed genetic diseases are identified and treated. His research focuses on applying novel methods that transform patient care by solving patients’ diagnostic odysseys, changing the courses of their clinical care or both. The program includes multi-omics patient profiling, integrative analyses, gene-phenotype characterization and functional genomic studies.

The first of the day’s two scientific sessions then followed with moderation of the first session by Thomas Cassini, MD, Associate Director of Genetics and Medical Genetics at Vanderbilt University Medical Center. The session was titled “Ending Diagnostic Odysseys and Advancing Genomic Medicine with Novel Diagnostic Approaches in the Undiagnosed Disease Network.”

The first of two sessions on the final day focused on “Ending Diagnostic Odysseys and Advancing Genomic Medicine with Novel Diagnostic Approaches in the Undiagnosed Diseases Network (UDN).” Individuals with rare, complex genetic diseases may spend years searching for a genetic cause of their condition (diagnostic odyssey). This session covered approaches to shortening time-to-diagnosis. Speakers discussed RNA-Seq diagnosis after failed genomic trio analysis, federated variant matching between patients, CAP/CLIA-certified RNA-Seq as a diagnostic, and profiling the epigenome with long-read sequencing.

The first speaker was Hector Rodrigo Mendez, MD, Stanford Center for Undiagnosed Diseases. His talk was titled “Biallelic Variants in RNU6ATAC Encomposs a Clinical Spectrum of Minor Spliceosome Disorders Through Minor Intron Retention Events.” He was followed by Nara Sobreira, MD, PhD, Johns Hopkins, who specializes in medical and pediatric genetics and she spoke on Match Maker and Variant Matcher of which she is one of the founders. Her main clinical and research focus is on identifying the genetic bases of rare phenotypes, mainly, phenotypes associated with cartilage tumors and vascular anomalies (including Ollier disease and Maffucci syndrome), and on understanding the physiopathology of these phenotypes to identify pharmacological strategies to treat them. 

Next was Pengfei Liu, PhD, Director, Medical Genetics and Multiomics Laboratory (MGML), Baylor College of Medicine, who discussed “Diagnostic Utilization of Trascriptome RNA Sequencing in the Undiagnosed Disease Network: From Research to CAP/CLIA-Certified Clinical Implementation.” He was followed by Andrew Stergachis, MD, PhD, Associate Professor of Medicine and Genome Sciences, University of Washington, speaking on “Long-Read Multi-Omics for Resolving the Genetic and Molecular Basis of Rare Diseases.”

The second scientific session was titled “Integrative Multi-Omics—Advancing Precision Health Through Cutting-Edge Technologies, Environmental Insights, and Community Engagement.” The session was co-chaired by Jill Moore, PhD, Assistant Professor, Genomics and Computational Biology, UMass Chan Medical School, and Rasheda Roshani, graduate student, Vanderbilt University. The first speaker was Leah Shriver, PhD, Washington University St. Louis, who described “Measuring Molecular Profiles: Advances in Genomics, Epigenomics, Proteomics, and Metabolomics.” Next was Maria Argos, PhD, Boston University School of Public Health, speaking on “Integrating Multi-Omics and Environmental Exposures for Precision Environmental Health.” The following speaker was Max Aung, PhD, MPH, Associate Director of Community Engagement and Science Communication at the Center for Translational Exposomics Research (CTER), University of Southern California, who described “The Role of Community Outreach and Engagement in Multi-Omic Studies.” The final speaker was Zhiping Weng, PhD, Professor and Chair, Department of Genomics and Computational Biology, UMass Chan Medical School, discussed “Multi-Omics for Health and Disease Consortium (MOHD).”